deltaDOT Announces Manufacturer for 1D Protein/Nucleic Acid Analysis System

deltaDOT has announced that Lathrop Engineering has been awarded the manufacturing contract for its first two commercial products, a protein/nucleic acid analysis system and a DNA sequencer. These products are based on deltaDOT's proprietary Label Free Intrinsic Imaging (LFII) technology.

Both the Peregrine Protein/Nucleic Acid analysis system and the Merlin DNA sequencer are designed to offer unrivalled sensitivity, ultra high-speed throughput and low running costs.

Tony Baxter, CEO of deltaDOT said "We are very impressed with Lathrop's manufacturing capabilities and are confident in their ability to deliver high-quality systems with fast delivery times.”

He adds, “Having previously developed a range of biomedical products, including electrophoresis systems, Lathrop understands the stringent tolerances of this business and the requirements of manufacturing precision instrumentation.”

Further he said, “Their technical abilities, industry experience, and short development cycles are all advantages that we can pass on directly to our customers."

deltaDOT's biomolecule detection technique, LFII, is derived from recent innovations in high-energy physics research and their application in modern biochemical analysis.

Unlike conventional techniques, the technology does not require target molecules to be labelled and therefore enables superior data quantification, while reducing throughput times, operating costs and health and safety issues.

"Both the management and engineering teams at Lathrop are tremendously excited to be working with deltaDOT on the Peregrine and Merlin projects," said Bruce Richardson, VP of Engineering for Lathrop.
He adds, "Founded in their background and field knowledge, both in the bioscience and particle physics, deltaDOT has created a core set of technologies that offer immediately recognizable benefits.”

“The ability to detect and quantify unlabelled proteins is a significant accomplishment and immensely important to the research and pharmaceutical development communities.”

Further he said, “This will also provide deltaDOT with a substantial competitive advantage in the biomedical market and we look forward to sharing in their future success."